Milestone Alert: First Patient Dosed in Phase 3 Trial for SD-101 in EB

The first patient has been enrolled in Paradigm Therapeutics’ Phase 3 clinical trial (SD-007) evaluating SD-101 (Zorblesia), an investigational topical cream for the treatment of chronic wounds and skin lesions associated with epidermolysis bullosa (EB).

SD-101 is the first topical therapy being developed to treat wounds and lesions across the entire skin surface in patients with three major EB subtypes. SD-101 accelerates wound healing by promoting formation of epithelial and granulation tissue. In addition, it is bacteriostatic, bactericidal, and effective in removing necrotic tissue. SD-101 also has keratolytic and anti-inflammatory effects.

SD-101 has received Rare Pediatric Disease and Orphan Drug designations from the US Food and Drug Administration (FDA). Upon regulatory approval, Paradigm will be eligible to receive a Priority Review Voucher (PRV).

The SD-007 study is a multicenter, prospective, randomized, double blind, placebo-controlled trial designed to evaluate the efficacy and safety of SD-101 in patients with EB simplex (EBS), recessive dystrophic EB (RDEB), and junctional EB (JEB). The study will assess the closure of selected chronic target wounds, changes in the body surface area affected by wounds and lesions, and improvements in itching.

Approximately 80 patients aged 28 days to 12 years old are planned for enrollment at 17 clinical sites across 14 countries, spanning North America, South America, Europe, Asia, and Australia. Participants will apply SD-101 cream or the study comparator daily over the entire body for two months, according to the study protocol. Patients who complete SD-007 will be eligible to participate in a subsequent study, SD-008, providing an opportunity for continued treatment.

“Initiating this Phase 3 study is an important milestone in the development of SD-101 (Zorblesia),” says Robert Ryan, PhD, President and Chief Executive Officer of Paradigm Therapeutics, in a news release. “Results from our completed Phase 2 and Phase 3 clinical studies support continued evaluation of daily, whole-body application, including its potential to promote target-wound closure and reduce the overall area of skin affected by lesions. We are committed to completing the development program and advancing SD-101 toward potential regulatory approval, with the goal of expanding treatment options for patients and families affected by this debilitating disease. We are also working with potential partners to support the therapy’s future global development and availability.”